COVID‐19 and Toll‐Like Receptor 4 (TLR4): SARS‐CoV‐2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation

Abstract

Causes of mortality from COVID‐19 include respiratory failure, heart failure, and sepsis/multiorgan failure. TLR4 is an innate immune receptor on the cell surface that recognizes pathogen‐associated molecular patterns (PAMPs) including viral proteins and triggers the production of type I interferons and proinflammatory cytokines to combat infection. It is expressed on both immune cells and tissue‐resident cells. ACE2, the reported entry receptor for SARS‐CoV‐2, is only present on ~1‐2% of the cells in the lungs or has a low pulmonary expression, and recently, the spike protein has been proposed to have the strongest protein‐protein interaction with TLR4. Here, we review and connect evidence for SARS‐CoV‐1 and SARS‐CoV‐2 having direct and indirect binding to TLR4, together with other viral precedents, which when combined shed light on the COVID‐19 pathophysiological puzzle. We propose a model in which the SARS‐CoV‐2 spike glycoprotein binds TLR4 and activates TLR4 signalling to increase cell surface expression of ACE2 facilitating entry. SARS‐CoV‐2 also destroys the type II alveolar cells that secrete pulmonary surfactants, which normally decrease the air/tissue surface tension and block TLR4 in the lungs thus promoting ARDS and inflammation. Furthermore, SARS‐CoV‐2‐induced myocarditis and multiple‐organ injury may be due to TLR4 activation, aberrant TLR4 signalling, and hyperinflammation in COVID‐19 patients. Therefore, TLR4 contributes significantly to the pathogenesis of SARS‐CoV‐2, and its overactivation causes a prolonged or excessive innate immune response. TLR4 appears to be a promising therapeutic target in COVID‐19, and since TLR4 antagonists have been previously trialled in sepsis and in other antiviral contexts, we propose the clinical trial testing of TLR4 antagonists in the treatment of severe COVID‐19. Also, ongoing clinical trials of pulmonary surfactants in COVID‐19 hold promise since they also block TLR4.

References 164

1. 1.

   Coronavirus disease (COVID-2019) situation reports. 2020.

   Not in our library

2. 2.

   Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

   Not in our library10.1016/s0140-6736(20)30183-5

3. 3.

   Guan W. J., Ni Z. Y., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine. 2020;382(18):1708-1720.

   Not in our library10.1056/nejmoa2002032

4. 4.
   COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs · 2020

   No notice
5. 5.

   Shereen M. A., Khan S., Kazmi A., Bashir N., Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. Journal of Advanced Research. 2020;24:91-98.

   Not in our library10.1016/j.jare.2020.03.005

6. 6.

   Wu A., Peng Y., Huang B., et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host & Microbe. 2020;27(3):325-328.

   Not in our library10.1016/j.chom.2020.02.001

7. 7.
   Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies · 2020

   No notice
8. 8.

   Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.

   Not in our library10.1016/j.cell.2020.02.052

9. 9.

   Wan Y., Shang J., Graham R., Baric R. S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of Virology. 2020;94(7).

   Not in our library10.1128/jvi.00127-20

10. 10.
    Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection · 2020

    No notice
11. 11.
    A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

    No notice
12. 12.

    Mogensen T. H., Paludan S. R. Reading the viral signature by toll-like receptors and other pattern recognition receptors. Journal of Molecular Medicine (Berlin, Germany). 2005;83(3):180-192.

    Not in our library10.1007/s00109-004-0620-6

13. 13.

    Seow J., Graham C., Merrick B., et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology. 2020;5(12):1598-1607.

    Not in our library10.1038/s41564-020-00813-8

14. 14.

    Dekleijn D., Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovascular Research. 2003;60(1):58-67.

    Not in our library10.1016/s0008-6363(03)00348-1

15. 15.

    Turner N. A. Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). Journal of Molecular and Cellular Cardiology. 2016;94:189-200.

    Not in our library10.1016/j.yjmcc.2015.11.002

16. 16.

    Rosadini C. V., Kagan J. C. Early innate immune responses to bacterial LPS. Current Opinion in Immunology. 2017;44:14-19.

    Not in our library10.1016/j.coi.2016.10.005

17. 17.

    Mesquita R. F., Paul M. A., Valmaseda A., et al. Protein kinase C-Calcineurin cosignaling downstream of toll-like receptor 4 downregulates fibrosis and induces wound healing gene expression in cardiac myofibroblasts. Molecular and Cellular Biology. 2014;34(4):574-594.

    Not in our library10.1128/mcb.01098-13

18. 18.

    Bhattacharyya S., Wang W., Qin W., et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight. 2018;3(13).

    Not in our library10.1172/jci.insight.98850

19. 19.

    MacRedmond R., Greene C., Taggart C. C., McElvaney N., O'Neill S. Respiratory epithelial cells require Toll-like receptor 4 for induction of human β-defensin 2 by lipopolysaccharide. Respiratory Research. 2005;6(1).

    Not in our library10.1186/1465-9921-6-116

20. 20.

    Chow J. C., Young D. W., Golenbock D. T., Christ W. J., Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. The Journal of Biological Chemistry. 1999;274(16):10689-10692.

    Not in our library10.1074/jbc.274.16.10689

21. 21.

    Alexopoulou L., Holt A. C., Medzhitov R., Flavell R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413(6857):732-738.

    Not in our library10.1038/35099560

22. 22.
    TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis · 2017

    No notice
23. 23.
    The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation · 2016

    No notice
24. 24.
    The Role of TLR2, TLR4, and TLR9 in the Pathogenesis of Atherosclerosis · 2016

    No notice
25. 25.

    Patra M. C., Shah M., Choi S. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Seminars in Cancer Biology. 2020;64:61-82.

    Not in our library10.1016/j.semcancer.2019.05.002

26. 26.

    García Bueno B., Caso J. R., Madrigal J. L. M., Leza J. C. Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases. Neuroscience and Biobehavioral Reviews. 2016;64:134-147.

    Not in our library10.1016/j.neubiorev.2016.02.013

27. 27.

    Liu Y., Yin H., Zhao M., Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clinical Reviews in Allergy and Immunology. 2014;47(2, article 8402):136-147.

    Not in our library10.1007/s12016-013-8402-y

28. 28.

    Biancardi V. C., Bomfim G. F., Reis W. L., al-Gassimi S., Nunes K. P. The interplay between angiotensin II, TLR4 and hypertension. Pharmacological Research. 2017;120:88-96.

    Not in our library10.1016/j.phrs.2017.03.017

29. 29.

    Mukherjee S., Karmakar S., Babu S. P. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. The Brazilian Journal of Infectious Diseases. 2016;20(2):193-204.

    Not in our library10.1016/j.bjid.2015.10.011

30. 30.

    Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. Journal of Medical Virology. 2020;92(10):2105-2113.

    Not in our library10.1002/jmv.25987

31. 31.

    Zhou Z., Ren L., Zhang L., et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host & Microbe. 2020;27(6):883-890.e2.

    Not in our library10.1016/j.chom.2020.04.017

32. 32.
    SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues · 2020

    No notice
33. 33.

    Voelker D. R., Numata M. Phospholipid regulation of innate immunity and respiratory viral infection. The Journal of Biological Chemistry. 2019;294(12):4282-4289.

    Not in our library10.1074/jbc.aw118.003229

34. 34.
    Alveolar lipids in pulmonary disease. A review · 2020

    No notice
35. 35.

    Chroneos Z. C., Sever-Chroneos Z., Shepherd V. L. Pulmonary surfactant: an immunological perspective. Cellular Physiology and Biochemistry. 2010;25(1):13-26.

    Not in our library10.1159/000272047

36. 36.

    Kolomaznik M., Nova Z., Calkovska A. Pulmonary surfactant and bacterial lipopolysaccharide: the interaction and its functional consequences. Physiological Research. 2017;66(Supplement 2):S147-S157.

    Not in our library10.33549/physiolres.933672

37. 37.

    Kuronuma K., Mitsuzawa H., Takeda K., et al. Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2. The Journal of Biological Chemistry. 2009;284(38):25488-25500.

    Not in our library10.1074/jbc.m109.040832

38. 38.

    Abate W., Alghaithy A. A., Parton J., Jones K. P., Jackson S. K. Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains. Journal of Lipid Research. 2010;51(2):334-344.

    Not in our library10.1194/jlr.m000513

39. 39.
    Clinical characteristics of 82 cases of death from COVID-19 · 2020

    No notice
40. 40.

    Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846-848.

    Not in our library10.1007/s00134-020-05991-x

Cited by papers we hold 5

• Changes in peripheral blood mononuclear cell electrical properties in response to viral exposure and vaccination · 2025
  Not checked
• The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets · 2024
  No notice
• Identifying potential pharmacological targets and mechanisms of vitamin D for hepatocellular carcinoma and COVID-19 · 2022
  Not checked
• SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
  No notice
• The Role of Epithelial Damage in the Pulmonary Immune Response · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.